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(PDLFs) [11] . In their experiments, the release of growth factors was controlled by BMP 2 containing basic gelatin microspheres and IGF 1 containing acidic gelatin microspheres, which were incorpo rated into glycidyl methacrylated dextran (Dex GMA) scaffolds.
We have previously developed a thermosensitive injectable chitosan gel to deliver BMP 2. It has been found to significantly en hance the osteoblastic differentiation of mouse osteoblast precur sor cells and the mineralization of human embryonic palatal mesenchymal cells [25] . Chitosan gels have been used due to their excellent biocompatibility, enzyme regulated degradation, and high efficacy of drug therapy [2,3,9,25 28] . Additionally, therapeu tic agents are released via the diffusion or biodegradation of the chitosan polymers [5, 25 28] . The purpose of this study was to cre ate and characterize a sequential delivery system consisting of a chitosan gel and gelatin microspheres (MSs) to achieve a sequen tial release of BMP 2 and IGF 1. We hypothesized that an initial release of BMP 2 from the chitosan gel followed by the release of IGF 1 from the gelatin MSs would enhance osteoblastic activity of bone cells. In this study, we made glyoxal cross linked gelatin MSs for delivery of IGF 1, which were then encapsulated into the chitosan gel formulation. Furthermore, we aimed to characterize the degree of cross linking, degradation, release rate and cytotox icity of the delivery system. We also evaluated osteoblastic activity by measuring ALP specific activity of preosteoblast W 20 17 mouse bone marrow stromal cells.
Materials and methods

Materials
Chitosan (P310 kDa, 75% or greater degree of deacetylation), disodium b GP (glycerol 2 phosphate disodium salt hydrate; cell culture grade), and glyoxal (40 wt.%) were purchased from Sig ma Aldrich (St Louis, MO). Gelatin type B, olive oil, acetone, and ethanol were all purchased from Fisher Scientific (Fair Lawn, NJ). All other chemicals were reagent grade and were used as received. Human bone morphogenetic protein 2 (BMP 2) was obtained from PeproTech (Rocky Hill, NJ) and recombinant human insulin like growth factor I (IGF 1) was purchased from R&D Systems (Minne apolis, MN). Fetal bovine serum (FBS), Trypsin EDTA, L glutamine, antibiotic antimycotic, phosphate buffered saline (PBS), and Dul becco's modified Eagle's medium (DMEM) were all purchased from Invitrogen™ (Eugene, OR). W 20 17 cells were cultured as per American Type Culture Collection (ATCC) instructions.
Preparation of gelatin microspheres
Gelatin MSs were prepared using a water in oil emulsion tech nique. Briefly, a gelatin solution was prepared by dissolving 1 g gel atin powder in 10 ml distilled water at 50°C. The solution was then added dropwise to 60 ml olive oil, which was preheated to 50°C while stirring at 500 rpm using a straight blade impeller. The gel atin solution was allowed to emulsify for 10 min. Subsequently, the entire emulsification bath was chilled to 4°C on ice with con tinuous stirring at 500 rpm for 40 min, and gelatin MSs were formed. The gelatin MSs were collected by filtration and washed with chilled acetone and ethanol. Finally, the obtained gelatin MSs were freeze dried overnight.
Cross linking of gelatin MSs
The prepared gelatin MSs were dispersed into an aqueous eth anol solution containing different concentrations of glyoxal (10, 20, 50, or 100 mM) and stirred at room temperature for cross link ing for 10 h. The cross linked gelatin MSs were rinsed twice with an aqueous ethanol solution to remove the residual cross linking agent on their surfaces and then freeze dried overnight. They were then sieved to obtain particles ranging from 50 to 100 lm.
Fourier transform infrared spectroscopy (FTIR) spectra
In order to investigate chemical structure of both gelatin MSs and cross linked gelatin MSs, FTIR spectra were obtained using a Nicolet FTIR infrared microscope coupled to a PC with analysis software. Samples were placed in the holder directly in the IR laser beam. All spectra were recorded by transmittance mode (100 times scanning, 650 4000 cm 1 ).
Degree of cross linking
Degree of cross linking of the gelatin MSs was determined by ninhydrin assay, which was used to determine the percentage of free amino groups remaining in the gelatin MSs after cross linking. The cross linked gelatin MSs were prepared with different concen trations of glyoxal (10, 20, 50, or 100 mM). The samples were heated in the ninhydrin solution at 100°C for 10 min, and the light absorbance at 550 nm was recorded using a microplate reader (TE CAN Infinite F50). Glycine (Fisher Scientific, Fair Lawn, NJ) was used as an amino acid nitrogen standard at various known concen trations. The degree of cross linking (D c ) of the samples was calcu lated following the equation D c = [(A B)/A] Â 100, where A is mole fraction of free amino group in un cross linked gelatin MSs and B is mole fraction of free amino group in cross linked gelatin MSs.
Swelling of gelatin MSs at different temperatures
To evaluate the effect of cross linking on water stability of the gelatin MSs, the swelling characteristic of the gelatin MSs was investigated at different temperatures. The swelling of the gelatin MSs and the cross linked gelatin MSs (50 mM) were observed using a microscope (Nikon ECLIPSE TE 2000 U). The dried samples were placed into a container with PBS (pH 7.4) and incubated at 4 or 37°C for 3 days. Photomicrographs of the gelatin MSs were pro cessed at 6 h, 1 day, and 3 days of incubation using MetaVue software.
Cytotoxicity
W 20 17 cells were grown and maintained in DMEM media with 10% FBS, 1% antibiotic/antimycotic mixture, 5 ml L glutamine (200 mM), and sodium pyruvate. This cell line has been used in an ASTM F2131 to evaluate activity of BMP 2 in vitro. Cell culture was achieved in an incubator supplied with 5% CO 2 at 37°C. The culture medium was changed every 3 days. In order to investigate the cytotoxicity of the gelatin MSs, the W 20 17 cells were cultured in the DMEM media containing the gelatin MSs. Cells were seeded in 24 well plates at a density of 30,000 cells per well and incubated with 10 mg of the gelatin MSs for 3 days. After incubation of 1 and 3 days, the number of viable cells was determined quantitatively using a Cell Titer 96AQueous One Solution (MTS) assay according to the manufacturer's instructions. Before the assay, the cellular morphology was observed qualitatively using a microscope (Nikon, ECLIPSE TE 2000 U). Photomicrographs of cells were processed using Nikon MetaVue software.
Gelatin MSs encapsulated chitosan gel composites
A 1.5% (w/v) chitosan solution was prepared by stirring pow dered chitosan in 0.75% (v/v) aqueous acetic acid at room temper ature overnight. The insoluble particles in the chitosan solution were removed by filtration. A 50% (w/v) b GP solution was pre pared in distilled water and sterilized using PES syringe filters with 0.22 lm pore size (MillexTM, MA) and stored at 4°C. 50 ml of chitosan solution was dialyzed at room temperature against 1 l of distilled water for 7 days with daily changes of water (1 l) in an 8 kDa cutoff dialysis membrane to reduce the acetic acid con tent. The final pH value of the chitosan solution was 6.3. The dia lyzed chitosan solution was autoclaved at 121°C for 20 min, cooled down to room temperature, and stored at 4°C. The cross linked gelatin MSs were then encapsulated into the chitosan solu tion on ice and vortexed. Sterilized, ice cold b GP solution (2.31 M) was added drop by drop to the chitosan solution under stirring conditions in an ice bath. The final concentration of b GP in the chitosan solution was 88 mM, and the final pH value of the chito san gel formulation was 7.2. Each gel forming solution was al lowed to completely become a gel in an incubator for 3 h at 37°C.
Dissolution rate
Gelatin is an amphoteric protein containing both positively charged and negatively charged amino acids. It easily dissolves in water at body temperature, releasing amino acids. In this study, the cross linked gelatin MSs or the cross linked gelatin MS loaded chitosan gel were placed in a container containing 2 ml of PBS (pH 7.4) and incubated at 37°C for 5 days. At predetermined time points, 500 ll aliquots of the medium were sampled and the same amount of fresh PBS (pH 7.4) was added into each container. In the collected fractions, the cumulative amounts of dissolved proteins from the gelatin MSs or the combination were determined as a function of time by bicinchoninic acid (BCA) assay (Pierce, Rock ford, IL). The optical density of each sample was determined using a microplate reader at 562 nm (TECAN Infinite F50).
Scanning electron microscopy (SEM)
The surface morphology of the materials was observed to exam ine compatibility of gelatin MSs with a chitosan gel after implanta tion at body temperature. Three different materials, i.e. a chitosan gel, an un cross linked gelatin MS loaded chitosan gel, and a cross linked gelatin MS loaded chitosan gel, were prepared. They were incubated at 37°C for 5 h and lyophilized overnight (Freezone, LABCONCO). The samples were sputter coated with gold and examined under a scanning electron microscope (FEI, USA) oper ated at 15 kV.
In vitro release studies
IGF 1 release
In vitro IGF 1 release profiles from cross linked gelatin MSs or a cross linked gelatin MS loaded chitosan gel were examined for 1 week. IGF 1 loading was achieved by a method of adsorption. The cross linked gelatin MSs were loaded with IGF 1 by swelling in aqueous IGF 1 solutions (IGF 1(MSs)). IGF 1 (isoelectric point (IEP) = 8.6) is positively charged, and therefore, negatively charged type B gelatin forms a polyionic complexation with IGF 1 [23, 29 31] . IGF 1 solution was dripped onto the microparticles at a vol ume of 25 ll per mg of the cross linked gelatin MSs. The resulting mixture was vortexed and incubated at 4°C for 10 h before freeze drying. Eventually, 50 ng ml -1 of IGF 1 was present within each sample (IGF 1(MSs)). The IGF 1 loaded gelatin MSs were then encapsulated into a chitosan gel formulation (IGF 1(gel + MSs)). The IGF 1 loaded microparticles were added into the chitosan gel formulation on ice and vortexed. 88 mM of cold b GP solution was added into the mixture to complete the gel forming solution. Each gel forming solution was allowed to completely become a gel in an incubator at 37°C. IGF 1(MSs) or IGF 1(gel + MSs) was placed in a container con taining 2 ml of PBS (pH 7.4) and incubated at 37°C for a week. At designated time points, 300 ll aliquots of the release medium were sampled and the same amount of fresh PBS (pH 7.4) was added into each container. In the collected fractions, the cumulative release amounts of IGF 1 from the materials were determined as a function of time by an IGF 1 ELISA kit (RayBio, GA). Briefly, 100 ll of the ob tained samples were pipetted into a 96 well IGF 1 microplate coated with anti human IGF 1 and incubated at 4°C overnight. After washing each well with wash buffer provided by the ELISA kit for a total of four washes, 100 ll of biotinylated anti human IGF 1 was added to each well and incubated at room temperature for 1 h. After repeating the washing step, each well was filled with 100 ll of horseradish peroxidase streptavidin solution and incu bated at room temperature for 45 min. After the washing step, 100 ll of TMB (3,3 0 ,5,5 0 tetramethylbenzidine) was added to each well and incubated for 30 min at room temperature in the dark. Fi nally, 50 ll of stop solution was added into each well. The optical density of each well was determined using a microplate reader at 450 nm (TECAN Infinite F50).
BMP 2 release
The in vitro BMP 2 release profile from the chitosan gel was investigated for 1 week. BMP 2 solution was added directly into the chitosan solution on ice and vortexed. 88 mM of cold b GP solu tion was added into the mixture to complete the gel forming solu tion. Each gel forming solution containing BMP 2 was allowed to completely become a gel in an incubator at 37°C. Eventually, 50 ng ml -1 of BMP 2 was present within each sample (BMP 2 (Gel)). BMP 2 (Gel) was placed in a container containing 2 ml of PBS (pH 7.4) and incubated at 37°C for a week. At designated time points, 300 ll aliquots of the release medium were sampled and the same amount of fresh PBS (pH 7.4) was added into each con tainer. In the collected fractions, the cumulative release amounts of BMP 2 from the chitosan gels were determined as a function of time by a BMP 2 ELISA kit (R&D systems, MN). Briefly, 50 ll of the obtained supernatant was pipetted into a 96 well BMP 2 microplate coated with a mouse monoclonal antibody and incu bated for 2 h at room temperature. After washing each well with wash buffer provided by the ELISA kit for a total of four washes, 200 ll of BMP 2 conjugate was added to each well and incubated at room temperature for 2 h. After repeating the washing step, each well was filled with 200 ll of BMP 2 substrate and incubated at room temperature for 30 min in the dark. Finally, 50 ll of stop solution was added into each well. The optical density of each well was determined using a microplate reader at 450 nm with a cor rection setting of 540 nm (TECAN Infinite F50).
In vitro analysis
Effect of growth factors on ALP specific activity of W 20 17
To better evaluate the sequential delivery of growth factors on the cell responses, we first established a growth factor cell re sponse calibration model. We studied ALP activity as an indicator of early osteoblastic differentiation to designated singular or com bination of BMP 2 and IGF 1 listed in Table 1 . In this experiment, W 20 17 cells were treated with growth factors (BMP 2, IGF 1, or combinations), and ALP activity and double stranded DNA (dsDNA) of W 20 17 cells were determined. The cells were seeded in 24 well plates at a density of 30,000 cells per well and cultured for 7 days. On days 1 and 3, 50 ng ml -1 of each growth factor or their combination was added into the culture medium as shown in Table 1 . The culture medium was changed every 3 days.
At designated time points (5 and 7 days) the medium was re moved from the cell culture. The cell layers were washed twice with PBS (pH 7.4) and then lysed with 1 ml of 0.2% Triton X 100 and three freeze thaw cycles, which consisted of freezing at 80°C for 30 min immediately followed by thawing at 37°C for 15 min. 50 ll aliquots of the cell lysates were sampled and added to 50 ll of working reagent in a 96 well assay plate. The working reagent contains equal parts (1:1:1) of 1.5 M 2 amino 2 methyl should be undertaken to determine the long term effects of the delivery system with regard to release profile, degradation behav ior, and calcium mineral deposition.
Conclusions
In this study we have synthesized and characterized a chitosan gel/gelatin MS based delivery system. We also demonstrated a sequential administration of two model proteins, BMP 2 and IGF 1 by this delivery system. The controlled releases of these two pro teins are regulated by the degree of cross linking of gelatin MSs, the encapsulation of gelatin MSs into the chitosan gel, and the interactions between proteins and carriers. The enhanced effect of sequential administration of BMP 2 and IGF 1 on early osteo blastic differentiation marker activity was clearly validated by the addition of growth factors to the medium and the experimental delivery system. The advantage of this protocol is that the delivery effect can be validated and can be extended to other delivery sys tems and proteins.
